SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2003
United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)| | | | | |
| Delaware | | 000-26301 | | 52-1984749 |
| |
| |
|
(State or Other
Jurisdiction of
Incorporation) | | (Commission
File Number) | | (I.R.S. Employer
Identification Number) |
| | | | | |
1110 Spring Street
Silver Spring, MD | | |
20910 | |
| | |
| |
| (Address of Principal Executive Offices) | | | (Zip Code) | |
Registrant’s telephone number, including area code:
(301) 608-9292
Item 5. Other Events.
On May 13, 2003, United Therapeutics Corporation (the “Company”) issued a press release, a copy of which is attached as Exhibit 99.1, announcing that Roger Jeffs, Ph.D., its President and Chief Operating Officer, has adopted a prearranged trading plan in accordance with Securities and Exchange Commission Rule10b5-1.
Item 7. Exhibits
| | | | |
| | Exhibit No. | | Description of Exhibit |
| |
| | 99.1 | | Press release dated May 13, 2003 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | UNITED THERAPEUTICS CORPORATION | |
| |
| Dated: May 13, 2003 | | By: | /s/ Paul A. Mahon | |
| | | |
Name: Paul A. Mahon
Title: SVP and General Counsel | |
EXHIBIT INDEX
| | | |
| Exhibit No. | | Description of Exhibit |
| |
| 99.1 | | Press release dated May 13, 2003 |
